| Name | Title | Contact Details |
|---|---|---|
Walter Leicher |
Group CEO | Profile |
LingaTech, Inc., a minority owned business, NMSDC MBE Certified, and is PA Small Diverse Business (SDB) Verified since 2014. We are a member of the Harrisburg Regional Chamber of Commerce & CREDC, and are registered with Hireveterans.com & PurplePlacement.com. We believe in technology innovation and customer partnership to deliver world class IT consultants, products and services. We provide high end consultants to partner with your organization to maximize your growth and achieve your IT goals. As your technology partner, when your business grows we grow with you. We offer software services in three major areas – Product development, Custom software development and Project Management. With professionals having more than 15 years of experience in software industry, our clients are assured of products/services that are of great quality.
Alliance Animal Health is a multi-site business partner to veterinarians across the US. Alliance Animal Health allows veterinarians to continue to practice medicine independently while providing resources and assistance in business operations. Veterinarians retain all the benefits of being an independent practice, but gain the additional advantages associated with becoming part of a larger organization. These include access to professional marketing, inventory management expertise, purchasing power, recruiting support, collaborative synergies, and financial resources. Our network of general practice and emergency hospitals is as individual as you, and we like it that way! Our network of highly skilled partners and associate veterinarians work hard to deliver the quality of personalized care and attention that our profession deserves. We pride ourselves on maintaining a culture of open communication and collaboration to remain innovative and cutting edge in todays veterinary environment without disrupting the medical autonomy of our qualified veterinarians.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.